Trial Profile
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Dec 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Doxorubicin; Etoposide; Hydrocortisone; Hydrocortisone; Methotrexate; Methotrexate; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Plasmablastic lymphoma
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2021 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 02 Dec 2020 According to a Rutgers Cancer Institute media release, data from this study will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually from December 5-8.